Włóknienie płuc: badanie fazy II leku TX000045
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Badania kliniczne w obszarze: nadciśnienie tętnicze, prowadzone w ośrodkach w mieście Kraków. Zobacz też wszystkie badania: nadciśnienie tętnicze w Polsce.
22 badania: 21 rekrutuje, 1 wkrótce zacznie.
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic…
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
Optimal Medical Treatment of Difficult-to-treat Hypertension
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Novel Setup Algorithm for Cardiac Neuromodulation Therapy
DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 3 października 2026.